The U.S. Supreme Court has agreed to review a case that has significant implications for consumers and drug makers concerning lawsuits that are filed over product warnings.

The case involves hundreds of lawsuits that were filed by women who claim they suffered bone fractures after taking Fosamax, a Merck (MRK) drug used to combat osteoporosis. Last year, a federal appeals court overturned a lower court and decided the lawsuits should proceed, and last month, the U.S. Solicitor General urged the Supreme Court to review the matter.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy